BioRestorative Therapies(BRTX)
MELVILLE, NYBiotechnology
Focus: BioRestorative Therapies is a public biotechnology company focused on autologous stem cell therapy for degenerative diseases, currently in early-stage clinical development with minimal revenue generation.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at BioRestorative Therapies?
AI assessmentOnly pursue if you have high risk tolerance, believe deeply in the stem cell thesis, and can accept potential closure or forced M&A within 12-24 months.
Why Work Here
- Ground-floor opportunity in autologous stem cell therapy, a potentially transformative modality with significant commercial upside if BRTX-100 succeeds
- Public company status provides liquidity and potential equity upside compared to private biotech peers
Data completeness
5/9 — Partial
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
1 open
Revenue
$401K
Pipeline & Clinical Trials
BRTX-100
Lumbar Disc DiseaseClinical Trials (1)
NCT04042844A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
Phase 2Help build intelligence for BioRestorative Therapies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.